Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Nuveen Asset Management LLC reduced its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 28.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,668 shares of the company’s stock after selling 74,212 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Kura Oncology worth $1,591,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares in the last quarter. Harbor Advisors LLC bought a new stake in Kura Oncology in the fourth quarter valued at $87,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology in the fourth quarter valued at $90,000. Corton Capital Inc. bought a new stake in Kura Oncology in the fourth quarter valued at $99,000. Finally, Optimize Financial Inc bought a new stake in Kura Oncology in the fourth quarter valued at $100,000.

Kura Oncology Trading Up 1.9%

KURA stock opened at $6.42 on Wednesday. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market capitalization of $555.81 million, a price-to-earnings ratio of -2.72 and a beta of 0.50. The business has a 50 day simple moving average of $6.08 and a two-hundred day simple moving average of $7.83.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on KURA shares. Mizuho dropped their target price on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, May 19th. JMP Securities reissued a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Tuesday, April 29th. Wall Street Zen lowered Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.